Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 3/20 | 0.64 |
| ▸ | MAPK1 | P28482 | 5/20 | 0.62 |
| ▸ | LMNA | P02545 | 5/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 9/20 | 0.60 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.60 |
| ▸ | MAPT | P10636 | 8/20 | 0.58 |
| ▸ | ALDH1A3 | P47895 | 1/20 | 0.57 |
| ▸ | PKM | P14618 | 1/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
| ▸ | ATM | Q13315 | 1/20 | 0.56 |
| ▸ | HTT | P42858 | 1/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.53 |
| ▸ | RAB9A | P51151 | 1/20 | 0.52 |
| ▸ | GFER | P55789 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31588103 | 0.88 | GAA (0.64) | GAAMAPK1LMNASMN1; SMN2ALDH1A1 | |
| SCHEMBL23850699 | 0.88 | GAA (0.64) | GAAMAPK1LMNASMN1; SMN2ALDH1A1 | |
| SCHEMBL25870821 | 0.87 | MAPT (0.63) | GAAMAPK1LMNASMN1; SMN2ALDH1A1 | |
| SCHEMBL22455949 | 0.86 | MAPT (0.51) | GAAMAPK1LMNASMN1; SMN2ALDH1A1 | |
| SCHEMBL11555850 | 0.86 | MAPT (0.61) | GAAMAPK1LMNASMN1; SMN2ALDH1A1 | |
| SCHEMBL3485157 | 0.80 | GAA (0.69) | GAAMAPK1LMNASMN1; SMN2ALDH1A1 | |
| SCHEMBL3738174 | 0.78 | GAA (1.00) | GAAMAPK1LMNASMN1; SMN2ALDH1A1 | |
| SCHEMBL15109477 | 0.78 | MAPT (0.56) | GAAMAPK1LMNASMN1; SMN2ALDH1A1 | |
| SCHEMBL20598544 | 0.77 | GAA (0.69) | GAAMAPK1LMNASMN1; SMN2ALDH1A1 | |
| SCHEMBL12582165 | 0.77 | GAA (0.69) | GAAMAPK1LMNASMN1; SMN2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8193168-B2 | Use of a TRPM5 inhibitor to regulate insulin and GLP-1 release | REDPOINT BIO CORPORATION (US) | 2012-06-05 | — | — | US | disclosed |
| US-20080306030-A1 | Use of a TRPM5 Inhibitor to Regulate Insulin and GLP-1 Release | REDPOINT BIO CORPORATION (US) | 2008-12-11 | — | — | US | disclosed |
| US-20070207093-A1 | Hydrazone derivatives and uses thereof | LINQUAGEN CORP. | 2007-09-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070207093-A1 | Hydrazone derivatives and uses thereof | TAS2R1, TAS2R5, TAS1R1 | GAA 1015/4885MAPK1 1429/4885LMNA 4648/4885 |
| US-20080306030-A1 | Use of a TRPM5 Inhibitor to Regulate Insulin and GLP-1 Release | GLP1R, GIPR, TRPM5 | GAA 764/4885MAPK1 1453/4885LMNA 3506/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.